Bladder Cancer Coverage from Every Angle

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Posted: Friday, October 30, 2020

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses administering this combination regimen in patients with advanced disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.